Pfizer Inc. and Hospira, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire...
Hospira, Inc. has announced that the company has received 510(k) regulatory clearance from the FDA for the Plum 360 infusion...
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Pfizer Inc. announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company�s pending...
Hospira (now a subsidiary of Pfizer) filed a 351(k) application at the FDA on 16 December 2014 for Retacrit (epoetin...
In a Complete Response Letter relating to Retacrit (epoetin alfa biosimilar) from Hospira/Pfizer ,the FDA has rejected the application citing...
Results of an open-label extension study of Remsima/Inflectra (infliximab-biosimilar), from Hospira, in patients with Rheumatoid Arthritis, were presented at the...
According to a report by Bloomberg it was expected that biosimilars would be priced at 20-30% of the originator drug...
The National Institute of Care and Health Excellence (NICE) in draft guidance has recommended Remsima from Napp Pharma and Inflectra...
Napp Pharma has launched Remsima (infliximab biosimilar) in the United Kingdom at the same time as Hospira launched Inflectra (infliximab...